KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 13 years of Shares Outstanding data on record, last reported at $4.0 million in Q2 2023.

  • For Q2 2023, Shares Outstanding changed 0.0% year-over-year to $4.0 million; the TTM value through Jun 2023 reached $4.0 million, changed 0.0%, while the annual FY2022 figure was $4.0 million, 0.0% changed from the prior year.
  • Shares Outstanding reached $4.0 million in Q2 2023 per JAZZ's latest filing, down from $64.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $64.0 million in Q1 2023 and bottomed at $4.0 million in Q1 2019.
  • Average Shares Outstanding over 5 years is $31.4 million, with a median of $29.7 million recorded in 2019.
  • Peak YoY movement for Shares Outstanding: plummeted 93.38% in 2019, then skyrocketed 1499.68% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $56.1 million in 2019, then grew by 0.06% to $56.2 million in 2020, then plummeted by 92.88% to $4.0 million in 2021, then changed by 0.0% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $4.0 million in Q2 2023, $64.0 million in Q1 2023, and $4.0 million in Q4 2022.